RxDoctor Payments Data

Veronica Lupian, NP

Family · Middletown, NYNPI 1730895798

Payments from drug & device makers

$428in general payments, 2019–2025

Across 15 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$125
  • Lilly USA, LLC$63
  • Exact Sciences$50
  • AstraZeneca$46
  • Tactile Systems Technology Inc$45
  • Insulet Corporation$41
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$40895%
  • Education$205%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$428 in reported general payments places this provider in the 55th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$135,684
Medicare patients
616
Services billed
1,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lacosamide15$6,088
Scopolamine25$3,183
Diazepam63$3,177
Clobazam25$2,161
Levetiracetam29$1,640
Phenobarbital24$967
Baclofen19$693
Carbamazepine17$600
Divalproex Sodium18$566
Quetiapine Fumarate11$539
Clindamycin Phosphate12$512
Atorvastatin Calcium39$476
Olanzapine29$384
Propranolol Hcl11$381
Lamotrigine49$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$63$38429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,883 family providers in New York.

Other family in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →